WebJan 11, 2024 · High-volume disease per CHAARTED criteria was defined as the presence of visceral metastasis or ≥4 bone lesions with ≥1 beyond the vertebral bodies and pelvis; others were defined as... WebVolume 73, Issue 6, June 2024, Pages 834-844. Platinum Priority – Review – Prostate Cancer. Editorial by Rahul Aggarwal on pp. 845–846 of this issue. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta …
Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Pre…
WebApr 12, 2024 · Docetaxel plus ADT should be offered to patients with metastatic noncastrate prostate cancer with high-volume disease (four or more bone metastases, one or more of … Web2 days ago · Docetaxel plus ADT should be offered to patients with metastatic noncastrate prostate cancer with high-volume disease (four or more bone metastases, one or more of which is outside of the spine or ... daughtry feels like tonight youtube
Triplet therapy for prostate cancer - The Lancet
WebFeb 7, 2024 · Inclusion criteria were as follows: (1) pathological diagnosis of prostate cancer by biopsy and existence of high-volume tumor according to CHAARTED study 5; (2) presence of bone or visceral metastatic lesions by imageological examination; (3) progression to mCRPC after chemohormonal therapy (ADT plus docetaxel-based … WebDec 1, 2024 · The high-volume criteria of the CHAARTED trial meet the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies … WebJun 15, 2024 · While prostate cancer has an overall 5-year survival rate of 98.2%, patients with metastatic disease have a relatively dismal 30% 5-year survival rate [3]. In 1941, Charles Huggins and Clarence Hodges demonstrated that metastatic deposits from prostate cancer were hormonally sensitive [4]. daughtry blinding lights